Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How would you choose between Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation.
Related Questions
What are your top takeaways in GU Cancers from ESMO 2024?
How do you decide between radioligand therapy or cytotoxic chemotherapy in patients with metastatic castration-resistant prostate cancer with prior ARPI exposure who have cancer-related anemia?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
How do you manage prostate cancer in patients that cannot swallow pills?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
For an older patient with hormone-sensitive high-volume, high-risk prostate cancer with metastases to bone who developed toxicity with enzalutamide, what other oral AR blocker would you offer?
In which patients are referring for focal gland therapy for localized prostate cancer?
What are your top takeaways from ASCO GU 2025?
Would you continue serial PSMA PET scans after 2 negative scans for patients with a persistently rising PSA post-RT?
